B-2660-203
Research type
Research Study
Full title
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis
IRAS ID
278394
Contact name
Toby Maher
Contact email
Sponsor organisation
Blade Therapeutics, Inc.
Eudract number
2019-004998-34
Duration of Study in the UK
1 years, 8 months, 1 days
Research summary
This clinical study will test a new medication called BLD-2660 in patients with Idiopathic Pulmonary Fibrosis to find out if it can help. The study goal is to investigate the drug safety, biochemical and physiologic effects of the study drug (Pharmacodynamics) and how the study drug enters, moves through and exits the body (Pharmacokinetics). Different doses of study drug will be tested in this study to find the minimal dose at which the study drug is effective and interacts with its intended target.
The study is sponsored by Blade Therapeutics, Inc., a pharmaceutical company.
This study is being conducted in the United Kingdom. Up to 40 patients are planned to be enrolled. The expected duration of the study for each participant is 79 days.
REC name
London - City & East Research Ethics Committee
REC reference
20/LO/0277
Date of REC Opinion
21 May 2020
REC opinion
Further Information Favourable Opinion